Leucid Bio

Leucid Bio is a clinical-stage London biotech developing next-generation CAR-T cell therapies for refractory solid tumors. Spun out of King's College London in 2014 to commercialize two decades of research by Dr John Maher, the company's proprietary Lateral CAR platform redesigns the CAR receptor so its signalling domains sit laterally alongside the cell membrane - mimicking natural immune receptors to boost potency while reducing toxicity. Its lead candidate, LEU011, is an autologous NKG2D-targeting CAR-T therapy now in the Phase I/IIa AERIAL trial for refractory solid tumors.